Registry of Lobbyists
Version 2 of 8 (2003-04-09 to 2003-10-10) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Organization: |
CANADIAN ASSOCIATION FOR PHARMACY DISTRIBUTION MANAGEMENT
301A - 3800 STEELES AVENUE WEST WOODBRIDGE, ON L4L 4G9 Canada |
| Telephone number: | 905-265-1501 |
| Fax number: | 905-265-9372 |
| Responsible officer name and position during the period of this registration: | PHILIP J. ROSENBERG, PRESIDENT AND CEO |
| Description of the organization's activities: | THE CANADIAN ASSOCIATION FOR PHARMACY DISTRIBUTION MANAGEMENTESTABLISHED IN 1964 AS THE CANADIAN WHOLESALE DRUG ASSOCIATION, CAPDM IS A LEADING HEALTH CARE INDUSTRY ASSOCIATION WITH A SPECIAL FOCUS ON SUPPLY CHAIN MANAGEMENT. THE MEMBERSHIP CONSISTS OF FULL LINE DRUG WHOLESALERS/DISTRIBUTORS, PHARMACEUTICAL AND CONSUMER PRODUCTS MANUFACTURERS, HEALTH AND BEAUTY AIDS MANUFACTURERS AND OTHER SPECIALTY ORGANIZATIONS WITH AN INTEREST IN THE HEALTH CARE INDUSTRY. IN JANUARY, 2002 THE ASSOCIATION CHANGED ITS NAME FROM CWDA TO THE CANADIAN ASSOCIATION FOR PHARMACY DISTRIBUTION MANAGEMENT (CAPDM)MISSIONTHE ASSOCIATION S MISSION IS TO ASSIST ITS MEMBERSHIP IN THE COST EFFECTIVE AND EFFICIENT DISTRIBUTION OF HEALTH AND CONSUMER PRODUCTS AND SERVICES IN THE CANADIAN HEALTH CARE SYSTEM. ACTIVITIESTHE CAPDM: INCREASES VISIBILITY AND AWARENESS OF DRUG WHOLESALERS AND THEIR ESSENTIAL ROLE IN CANADA S HEALTH CARE SYSTEM PROMOTES THE USE OF CONSOLIDATED DISTRIBUTION FOR EFFICIENCY AND COST EFFECTIVENESS IN THE DELIVERY OF PRODUCTS AND SERVICES TO CANADA S PHARMACY SUPPLY CHAIN  INITIATES, BOTH INDIVIDUALLY AND THROUGH ITS INVOLVEMENT ON INDUSTRY-WIDE COMMITTEES AND TASK FORCES, IMPLEMENTATION OF IMPROVEMENTS IN THE SUPPLY CHAIN FOR PHARMACEUTICALS, OTCS, HEALTH AND BEAUTY AIDS AND CONSUMER PRODUCTS FACILITATES THE RESOLUTION OF INDUSTRY ISSUES THROUGH STRATEGIC ALLIANCES WITH TRADING PARTNERS  ASSISTS INDIVIDUAL MEMBER COMPANIES WITH ISSUES MANAGEMENT AND RESEARCH TAKES AN ADVOCACY ROLE ON BEHALF OF DRUG WHOLESALERS WITH GOVERNMENTS, THIRD PARTY PAYERS AND NATIONAL AND INTERNATIONAL TRADE ASSOCIATIONS MONITORS NEW DEVELOPMENTS AND TRENDS IN HEALTH CARE DELIVERY  PROVIDES SENIOR LEVEL COMMUNICATIONS LINKS WITH ITS MEMBERS, HEALTH CARE ASSOCIATIONS, GOVERNMENTS,3RD PARTY PAYERS, ACADEMICS, SERVICE PROVIDERS AND CUSTOMERS BY ORGANIZING FORMAL AND INFORMAL NETWORKING |
| Organization's membership or classes of membership: | DRUG WHOLESALER/DISTRIBUTOR - ACTIVELY ENGAGED IN BUSINESS AS A FULL SERVICER IN CANADA WHOSE PRIMARY BUSINESS IS THE ORDERLY DISTRIBUTION OF PHARMACEUTICAL PRODUCTS, SUNDRIES, HEALTH AND BEAUTY AIDS TO THE RETAIL TRADE AT LARGE, HOSPITALS OR SIMILAR INSTITUTIONS. INTEGRATED DRUGSTORE CHAIN -AS ABOVE BUT ALSO OPERATES, OWNS AND/OR FRANCHISES RETAIL STORES ENGAGED IN SELLING ABOVE PRODUCTS TO THE PUBLIC. INTEGRATED DRUGSTORE CHAIN MUST OWN AND OPERATE AT LEAST ONE DISTRIBUTION CENTRE THROUGH WHICH ITS DISTRIBUTION FUNCTION IS CARRIED OUT.ASSOCIATE(MANUFACTURER) - SELLS PRODUCTS THROUGH THE PHARMACEUTICAL INDUSTRY INCLUDING PHARMACEUTICAL PRODUCTS, SUNDRIES, AND/OR HEALTH AND BEAUTY AIDS AND WHICH SEPARATELY SELLS OR PROMOTES TO AND INVOICES DRUG WHOLESALERS/DISTRIBUTORS. ASSOCIATE (NON-MANUFACTURER)- DOES NOT MANUFACTURER PRODUCTS, YET SUPPLIES GOODS AND SERVICES TO THE PHARMACEUTICAL INDUSTRY. INTERNATIONAL MEMBER- ENGAGED IN SAME BUSINESS AS DRUG WHOLESALER/DISTRIBUTOR, INTEGRATED CHAIN OR ASSOCIATE OUTSIDE CANADA |
| Was the organization funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | KENNETH MULHALL |
| Position title: | VP, SUPPLY CHAIN |
| Public offices held: | N/A. Disclosure of this information was not a requirement prior to June 20, 2005. |
| Name: | PHILIP ROSENBERG |
| Position title: | PRESIDENT & CHIEF EXECUTIVE OFFICER |
| Public offices held: | N/A. Disclosure of this information was not a requirement prior to June 20, 2005. |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Aboriginal Affairs and Northern Development Canada, Canadian Transportation Agency (CTA), Competition Tribunal (CT), Environment Canada, Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Hazardous Materials Information Review Commission (HMIRC), Health Canada (HC), Industry Canada, Office of the Information and Privacy Commissioner (OIPC), Patented Medicine Prices Review Board (PMPRB), Procurement Review Board of Canada (PRB), Revenue Canada (RC), Statistics Canada (StatCan), Transport Canada (TC), Veterans Affairs Canada (VAC) |
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Other types: ANNUAL ORGANIZATIONAL REVIEW MEETING WITH TPD STAFF, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format |
| Subject Matter: Areas of Concern: | Aboriginal Affairs, Consumer Issues, Environment, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Science and Technology, Small Business, Taxation and Finance, Transportation |
| Subject Matter: Retrospective: | THERAPEUTIC PRODUCTS DIRECTORATE - ISSUES RELATED TO GMP GUIDELINES, COST RECOVERY REVIEWS.CONCERNS REGARDING DRUG WHOLESALERS WHO HAVE NOT APPLIED FOR AN ESTABLISHMENT LICENSE BUT CONTINUE TO OPERATE IN CANADA--WOULD LIKE TO SEE REQUIREMENT FOR PROVINCIAL REGISTRIES OF WHOLESALERS, WITH NOTIFICATION OF SAME TO FEDERAL TPD. WORKING WITH NAPRA AND PROVINCIAL REGULATORY BODIES TO ENSURE THAT PHARMACEUTICALS ARE SOLD IN APPROPRIATE RETAIL OUTLETS.WORKING WITH INDUSTRY CANADA TO MONITOR POTENTIAL SUPPLY DISRUPTIONS IN CANADA GIVEN TERRORIST ACTION IN US.WORKING WITH TPD "APETI" GROUP TO DEVELOP RECOMMENDED GUIDELINES FOR ELECTRONIC ORDERING OF CONTROLLED SUBSTANCES.PARTICIPATE IN ANNUAL ORGANIZATIONAL REVIEW WITH TPD. |
| Subject Matter: Prospective: | DEVELOP RECOMMENDATIONS FOR TPD RE: ELECTRONIC ORDERING OF CONTROLLED SUBSTANCES.PARTICIPATE IN INFORMATION WORKSHOP RE: NEW GMP GUIDELINE REVISIONS.PARTICIPATE IN MEDICAL DEVICES COST-RECOVERY REVIEW COMMITTEE AND BUSINESS IMPACT SUB-COMMITTEE.FOLLOW UP, COMMENT, POSSIBLY LOBBY ON ANY REGULATORY OR POLICY CHANGES FROM THERAPEUTIC PRODUCTS DIRECTORATE OR HEALTH OR INDUSTRY CANADA THAT IMPACT ON HEALTH CARE, PHARMACEUTICAL INDUSTRY, OR DISTRIBUTION OF PRODUCTS IN THE PHARMACY SUPPLY CHAIN; PARTICIPATE IN DISCUSSIONS ON NATIONAL PHARMACARE PROGRAM IF DIALOGUE DEVELOPS. RETAIN AN INTEREST IN REGULATORY FRAMEWOK FOR NATURAL HEALTH PRODUCTSALTHOUGH NOT AN AREA REQUIRING DIRECT INVOLVEMENT OF CWDA WATCHING WITH INTEREST THE ISSUE OF DIRECT-TO-CONSUMER ADVERTIZING OF PHARMACEUTICALS. |